Adagio Medical Holdings (ADGM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
Meeting called to order by Chair, with introductions of board members and officers present virtually.
Meeting hosted online, recorded, and accessible for six months on the corporate website.
Inspector of Election appointed and sworn in to oversee voting.
Board and executive committee updates
Board members Sandra Gardiner and Dr. Keyvan Mirsaeedi-Farahani introduced as present.
CEO Todd Usen and CFO/Chief Business Officer Deborah Kaster participated virtually.
Shareholder proposals
Two proposals presented: election of two class two directors and ratification of the independent auditor.
Nominees for director: Orly Mishan and Sean Salmon.
Proposal to ratify WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year 2026.
Latest events from Adagio Medical Holdings
- Ultra-low temperature ablation achieved 2.4% safety and 98% acute effectiveness in VT.ADGM
KOL event12 Jun 2026 - Ultra-low temperature VT ablation tech targets $5.8B market with FDA approval expected in 2026.ADGM
25th Annual Needham Virtual Healthcare Conference12 Jun 2026 - Ultra-low temperature VT ablation tech shows strong results and targets rapid U.S. market entry.ADGM
Small Cap Growth Virtual Investor Conference12 Jun 2026 - Pivotal VT ablation device shows 84% ICD shock freedom; FDA approval expected Q4 2026.ADGM
BofA Securities 2026 Health Care Conference12 Jun 2026 - Q3 2024 revenue up 351% year-over-year, but liquidity and going concern risks persist.ADGM
Q3 202411 Jun 2026 - 2024 revenue doubled, but net loss surged on impairment; FULCRUM-VT trial progressing rapidly.ADGM
Q4 202411 Jun 2026 - Net loss narrowed to $7.7M in Q1 2025, with FDA breakthrough and pivotal trial progress.ADGM
Q1 202511 Jun 2026 - Net loss narrowed, no Q2 2025 revenue, and FULCRUM-VT study nears full enrollment.ADGM
Q2 202511 Jun 2026 - Pivotal trial completed, $19M raised, $10.1M net loss, $4.7M cash; risks remain.ADGM
Q3 202511 Jun 2026